What Syncromune Inc.’s SYNC-T data reveals about the future of combination immunotherapy
Discover how Syncromune Inc.’s SYNC-T data could reshape combination immunotherapy. Find out what this means for cancer treatment innovation.
How Imviva Biotech is positioning allogeneic CAR-T therapy for autoimmune disease disruption
Can CTA313 redefine lupus treatment with CAR-T? Explore what Imviva Biotech’s early data means for autoimmune therapy innovation.
Tempest Therapeutics, Inc. bets on dual-targeting CAR-T to address antigen escape challenges
Tempest Therapeutics, Inc. advances TPST-2003 CAR-T data. Discover how dual-targeting could impact multiple myeloma treatment durability.
Is Rein Therapeutics, Inc.’s Phase 2 execution enough to differentiate LTI-03 in IPF
Rein Therapeutics advances LTI-03 in Phase 2 IPF trial. Find out what this means for fibrosis drug competition and clinical development today.
What Juniper Biosciences’ MSK collaboration means for radiation dose de-escalation strategies
Find out how Juniper Biosciences is using FMISO imaging to personalize radiation therapy and reduce toxicity in head and neck cancer.
What Biomolecular Holdings LLC’s platform patents reveal about the future of antibody engineering
Biomolecular Holdings LLC secures platform patents for tetrahedral antibodies. Discover what this means for the future of antibody engineering.
AbbVie Inc. secures strategic option on Kestrel Therapeutics Inc. amid KRAS innovation race
A new pan-KRAS approach enters Phase 1 backed by AbbVie Inc. Discover the implications for oncology pipelines and KRAS-driven cancers.
Could BioCardia, Inc.’s integrated platform overcome variability in cardiac regenerative treatments
Discover how BioCardia, Inc.’s Heart3D platform could reduce variability in cardiac cell therapy. Read the full analysis on what this means next.
Why Humacyte, Inc.’s vascular tissue platform is gaining attention in high-risk dialysis populations
Why Humacyte, Inc.’s ATEV is gaining traction in dialysis care. Explore clinical data, risks, and what comes next in vascular access innovation.
What ZORYVE cream’s infant indication means for non-steroidal eczema treatments
Can ZORYVE cream transform infant eczema care? Explore what this FDA filing means for non-steroidal treatment strategies today.